DK2319517T3 - Anvendelse af prodrugs til okulær, intravenøs administration - Google Patents

Anvendelse af prodrugs til okulær, intravenøs administration

Info

Publication number
DK2319517T3
DK2319517T3 DK10177382.8T DK10177382T DK2319517T3 DK 2319517 T3 DK2319517 T3 DK 2319517T3 DK 10177382 T DK10177382 T DK 10177382T DK 2319517 T3 DK2319517 T3 DK 2319517T3
Authority
DK
Denmark
Prior art keywords
ocular
prodrugs
application
intravenous administration
corticosteroid
Prior art date
Application number
DK10177382.8T
Other languages
English (en)
Inventor
Laura Rabinovich-Guilatt
Gregory Lambert
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of DK2319517T3 publication Critical patent/DK2319517T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DK10177382.8T 2006-06-01 2006-06-01 Anvendelse af prodrugs til okulær, intravenøs administration DK2319517T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/444,337 US20070281914A1 (en) 2006-06-01 2006-06-01 Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
EP06290902A EP1864668B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
US11/444,349 US20070280902A1 (en) 2006-06-01 2006-06-01 Method for treating eye disease or conditions affecting the posterior segment of the eye
EP06290901.5A EP1864667B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration

Publications (1)

Publication Number Publication Date
DK2319517T3 true DK2319517T3 (da) 2013-12-09

Family

ID=39712456

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10177382.8T DK2319517T3 (da) 2006-06-01 2006-06-01 Anvendelse af prodrugs til okulær, intravenøs administration
DK06290902.3T DK1864668T3 (da) 2006-06-01 2006-06-01 Anvendelse af prodrug til okulær, intravitreal administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06290902.3T DK1864668T3 (da) 2006-06-01 2006-06-01 Anvendelse af prodrug til okulær, intravitreal administration

Country Status (15)

Country Link
US (4) US20070280902A1 (da)
EP (4) EP2319517B1 (da)
JP (2) JP5284953B2 (da)
KR (1) KR101408317B1 (da)
CN (1) CN101553235B (da)
AU (1) AU2007267079B2 (da)
CA (1) CA2653902C (da)
DK (2) DK2319517T3 (da)
ES (1) ES2399976T3 (da)
HK (2) HK1110219A1 (da)
IL (1) IL195626A (da)
PL (4) PL2319517T3 (da)
PT (2) PT1864668E (da)
SI (1) SI1864668T1 (da)
WO (2) WO2007138113A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280902A1 (en) 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
EP2229174A1 (en) * 2007-12-04 2010-09-22 Novagali Pharma S.A. Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found INTRAOCULAR DRUG DELIVERY DEVICE AND ASSOCIATED METHODS
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
NZ628124A (en) * 2012-02-10 2016-06-24 Taiwan Liposome Co Ltd Pharmaceutical compositions to reduce complications of ocular steroid
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
PL3871662T3 (pl) * 2020-02-25 2023-11-20 Labomed Pharmaceutical Company S.A. Doustne roztwory zawierające octan fludrokortyzonu
JP2023542435A (ja) 2020-09-16 2023-10-06 サンテン エスエーエス 硝子体内投与のための水中油型油エマルション

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS5716818A (en) * 1981-04-25 1982-01-28 Green Cross Corp:The Steroid fatty emulsion
AU531588B2 (en) 1981-08-17 1983-09-01 Yoshitomi Pharmaceutical Industries, Ltd. Emulsifying water-insoluble steroid
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
AU4201189A (en) * 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH05132498A (ja) * 1991-11-08 1993-05-28 Asahi Glass Co Ltd ステロイド誘導体およびその製剤
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
NZ269773A (en) * 1993-08-02 1997-11-24 Commw Scient Ind Res Org Therapeutic compound conjugates; such conjugates comprise a compound bound to one to three acyl groups derived from fatty acids
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
EP0878197B1 (en) 1997-05-14 2002-08-21 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
IL121647A (en) * 1997-08-28 2001-07-24 Pharmateam Dev Ltd Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
EP1020194A4 (en) 1997-10-01 2003-05-21 Wakamoto Pharma Co Ltd OIL / WATER EMULSION COMPILATIONS
JP2000212067A (ja) * 1999-01-19 2000-08-02 Towa Yakuhin Kk 薬物含有エマルジョン製剤
ES2343512T3 (es) 2001-11-01 2010-08-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procedimiento y composicion para el tratamiento del ojo seco.
CA2510296A1 (en) * 2002-12-20 2004-07-15 Control Delivery Systems, Inc. Steroid compositions for intraocular use
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
ATE416761T1 (de) * 2003-09-22 2008-12-15 Onepharm Res & Dev Gmbh Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
ATE439123T1 (de) * 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
AU2005292145C1 (en) * 2004-10-01 2011-07-21 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
EP1929996B1 (en) 2004-11-09 2011-02-16 Novagali Pharma S.A. Ophthalmic emulsions containing an immunosuppressive agent
CN1905012A (zh) 2005-07-31 2007-01-31 新科实业有限公司 具有微驱动器的磁头折片组合及其磁盘驱动装置
US8109884B2 (en) 2005-09-23 2012-02-07 Kitchener Clark Wilson Dynamic metabolism monitoring system
US20070280902A1 (en) 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye

Also Published As

Publication number Publication date
SI1864668T1 (sl) 2013-04-30
EP1864668A1 (en) 2007-12-12
CA2653902C (en) 2015-03-17
CN101553235B (zh) 2012-12-05
US20070281913A1 (en) 2007-12-06
ES2399976T3 (es) 2013-04-04
JP2009538880A (ja) 2009-11-12
US20070280995A1 (en) 2007-12-06
PL1864667T3 (pl) 2014-01-31
EP2322183B1 (en) 2014-10-22
CN101553235A (zh) 2009-10-07
US20070281914A1 (en) 2007-12-06
HK1110221A1 (en) 2008-07-11
CA2653902A1 (en) 2007-12-06
IL195626A0 (en) 2009-09-01
EP1864668B1 (en) 2012-11-21
DK1864668T3 (da) 2013-03-04
EP2322183A1 (en) 2011-05-18
PL2322183T3 (pl) 2015-01-30
JP5284953B2 (ja) 2013-09-11
KR101408317B1 (ko) 2014-06-17
WO2007138114A1 (en) 2007-12-06
AU2007267079A1 (en) 2007-12-06
EP2319517A1 (en) 2011-05-11
JP5455624B2 (ja) 2014-03-26
PT1864668E (pt) 2013-02-26
JP2009538879A (ja) 2009-11-12
KR20090031373A (ko) 2009-03-25
HK1110219A1 (en) 2008-07-11
EP1864667A1 (en) 2007-12-12
EP1864667B1 (en) 2013-09-04
WO2007138113A1 (en) 2007-12-06
PL2319517T3 (pl) 2014-01-31
US9192567B2 (en) 2015-11-24
US20070280902A1 (en) 2007-12-06
IL195626A (en) 2017-05-29
PT1864667E (pt) 2013-11-18
AU2007267079B2 (en) 2013-01-31
EP2319517B1 (en) 2013-09-11
PL1864668T3 (pl) 2013-04-30
US8227452B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
DK2319517T3 (da) Anvendelse af prodrugs til okulær, intravenøs administration
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CO6351788A2 (es) Derivados de isoxazolo piridina
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
DK2148670T3 (da) Titrering af tapentadol
EA202091999A3 (ru) Применение ингибиторов dpp iv
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
DK2712610T3 (da) Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse
GT200800148A (es) Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal.
DK2380584T3 (da) Immunstimulerende fremgangsmåde
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
EP2386299A3 (en) 1-Amino-Alkylcyclohexane derivatives for the treatment of cochlear tinnitus
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament